Alnylam Pharmaceuticals Inc (NASDAQ:ALNY)
| 175.34 Delayed Data As of Sep 20 |  -0.14 / -0.08%Today’s Change | 174.41 Today|||52-Week Range 242.97 | -26.22% Year-to-Date |
Latest ALNY News | Press Releases
| Alnylam's (ALNY) Onpattro sNDA Gets FDA Advisory Committee Nod Sep 14 / Zacks.com - Paid Partner Content | Alnylam's (ALNY) Zilebesiran Meets Goals in Mid-Stage Study Sep 08 / Zacks.com - Paid Partner Content |
| Biotech Stock Roundup: MRNA's Vaccine Update, AMGN & HZNP Clear FTC Lawsuit & More Sep 08 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 175.66 |
| Today’s open | 176.00 |
| Day’s range | 174.41 - 179.49 |
| Volume | 565,315 |
| Average volume (3 months) | 565,981 |
| Market cap | $23.1B |
Data as of 3:59pm ET, 09/20/2023
Growth & Valuation
| Earnings growth (last year) | -29.11% |
| Earnings growth (this year) | +34.66% |
| Earnings growth (next 5 years) | +1.50% |
| Revenue growth (last year) | +22.88% |
| P/E ratio | NM |
| Price/Sales | 27.88 |
| Price/Book | -- |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| HZNPHorizon Therapeutics... | +0.09 | +0.08% |
| ESAIYEisai Co Ltd | -0.13 | -0.86% |
| ---- | ||
| INCYIncyte Corp | -0.23 | -0.38% |
Data as of 4:00pm ET, 09/20/2023
Financials
| Next reporting date | October 26, 2023 |
| EPS forecast (this quarter) | -$1.53 |
| Annual revenue (last year) | $1.0B |
| Annual profit (last year) | -$1.1B |
| Net profit margin | -109.04% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
